Suggested remit - To appraise the clinical and cost effectiveness of lenadogene nolparvovec within its marketing authorisation for treating Leber's hereditary optic neuropathy
Please note that following on from information received from the company, NICE has decided to suspend this evaluation from its current work programme. The timelines for this evaluation are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this evaluation will be available in due course.
 
Status Suspended
Technology type Medicine
Decision Selected
Process TA
ID number 1410

Project Team

Project lead Daniel Davies

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 June 2023 Suspended. Please note that following on from information received from the company, NICE has decided to suspend this evaluation from its current work programme. The timelines for this evaluation are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this evaluation will be available in due course.
07 February 2023 Invitation to participate
07 November 2022 - 07 December 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 July 2022 Please note that following on from advice received from the company this evaluation has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the evaluation will begin during late November 2022 when we will write to you about how you can get involved.
11 May 2022 Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
21 June 2021 - 02 July 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
21 June 2021 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 21 June to 2 July 2021.
01 September 2020 In progress. Topic is in progress
01 September 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lenadogene nolparvovec for treating Leber hereditary optic neuropathy. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
25 September 2018 - 23 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual